TL;DR
This study uncovers a novel regulatory axis in esophageal squamous cell carcinoma (ESCC) where the transcription factor E2F1 promotes tumor progression by suppressing microRNA-375 (miR-375). This suppression, in turn, leads to increased expression of sestrin 3 (SESN3), ultimately activating the PI3K/AKT signaling pathway, a key driver of cancer cell growth and survival.
What Problem Does This Paper Address?
Esophageal cancer, particularly ESCC, remains a significant global health challenge with poor survival rates, especially when diagnosed at advanced stages. While surgical and multimodal therapies have improved, there's a critical need for better diagnostic markers and therapeutic targets. The paper addresses the knowledge gap regarding the molecular mechanisms driving ESCC progression, specifically focusing on the role of E2F1, a known regulator of cell cycle and apoptosis, and its potential involvement in ESCC. The authors aim to elucidate E2F1's regulatory network within ESCC and identify actionable targets for intervention.
Methods
The researchers employed a multi-pronged approach:
- Bioinformatics Analysis: They utilized public databases (GEO, STRING, KEGG, TransmiR, Oncomine) to identify differentially expressed genes (DEGs) in ESCC, pinpoint E2F1 as a key upregulated gene, and explore its associated pathways and interacting miRNAs.
- Cell Culture and Manipulation: Standard ESCC cell lines (EC109, EC9706, KY150, YES2) and normal esophageal epithelial cells (HET1A) were used. Techniques like siRNA-mediated knockdown of E2F1 and SESN3, and transfection with miR-375 inhibitors/controls, were employed to study gene function.
- Molecular Assays:
- RT-qPCR and Western Blot: Used to quantify mRNA and protein expression levels of E2F1, miR-375, SESN3, and downstream signaling molecules (PI3K, AKT, p-AKT, MMP2, MMP9, Bax).
- Immunohistochemistry: Applied to visualize the expression and localization of E2F1 and SESN3 in ESCC tissues.
- Chromatin Immunoprecipitation (ChIP) Assay: Performed to confirm the direct binding of E2F1 to the miR-375 promoter.
- Luciferase Reporter Assay: Used to validate the interaction between miR-375 and SESN3.
- In situ Hybridization: Employed to assess the distribution of miR-375 in tumor tissues.
- Functional Assays:
- CCK-8 Assay: To evaluate cell proliferation.
- Transwell Assays (Migration and Invasion): To assess cell motility.
- Flow Cytometry: To measure apoptosis rates.
- In Vivo Tumorigenesis Assay: Xenograft models in nude mice were used to validate the findings in a living system, assessing tumor growth, weight, and proliferation markers (Ki-67).
Datasets
- Gene Expression Omnibus (GEO) Database: Specifically, GSE20347 (tumor and normal adjacent tissues from 17 ESCC patients) and GSE17351 (5 pairs of primary ESCC and adjacent normal esophageal mucosa) were used for initial DEG analysis.
- Human ESCC Tissue Samples: 38 pairs of ESCC and adjacent normal tissues were collected from the Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, for RT-qPCR, immunohistochemistry, and correlation analyses.
- ESCC Cell Lines: EC109, EC9706, KY150, and YES2 cell lines were used for in vitro experiments.
- Nude Mice: BALB/c nude mice were used for in vivo tumorigenesis assays.
Key Insights and Ideas
- E2F1 as a Master Regulator in ESCC: The study strongly implicates E2F1 not just as a marker but as a driver of ESCC progression, correlating its overexpression with poor prognosis and aggressive tumor characteristics.
- The miR-375 Connection: A key finding is that E2F1 directly binds to and suppresses the transcription of miR-375. This is significant because miR-375 is often considered a tumor suppressor.
- SESN3 as a Downstream Effector: The research identifies SESN3 as a direct target of miR-375. This suggests a cascade where E2F1's suppression of miR-375 leads to increased SESN3.
- PI3K/AKT Pathway Activation: The study demonstrates that the E2F1/miR-375/SESN3 axis converges on the PI3K/AKT pathway. E2F1's actions ultimately lead to the activation of this pathway, which is crucial for cell survival and proliferation in cancer.
- Therapeutic Potential: The findings highlight E2F1 and the miR-375/SESN3 axis as potential therapeutic targets for ESCC, offering new avenues for treatment development.
Key Results
- E2F1 Overexpression in ESCC: E2F1 was found to be significantly upregulated in ESCC tissues and cell lines compared to normal counterparts.
- E2F1 Promotes Malignancy: Silencing E2F1 in ESCC cells reduced proliferation, migration, and invasion, while increasing apoptosis. It also decreased pro-oncogenic proteins (MMP2, MMP9) and increased pro-apoptotic protein (Bax).
- miR-375 Suppression by E2F1: E2F1 directly binds to the miR-375 promoter and inhibits its transcription. miR-375 expression was reduced in ESCC tissues and negatively correlated with E2F1 levels.
- SESN3 as a miR-375 Target: SESN3 was identified as a target of miR-375, with its expression being inversely correlated with miR-375.
- E2F1/miR-375/SESN3 Axis: This axis was shown to regulate ESCC cell proliferation, migration, invasion, and apoptosis. Downregulation of miR-375 promoted these malignant behaviors, while SESN3 knockdown counteracted the effects of miR-375 inhibition.
- PI3K/AKT Pathway Modulation: E2F1 downregulation decreased PI3K/AKT pathway activity, while miR-375 inhibition restored it. SESN3 downregulation blocked this restoration. Similar trends were observed in vivo.
- In Vivo Validation: In nude mice, E2F1 knockdown reduced tumor growth, while miR-375 inhibition increased it. SESN3 knockdown also reduced tumor growth, confirming the axis's role in vivo.
Limitations and Future Work
- Sample Size: The authors acknowledge that the study used a relatively small sample size of 38 pairs of ESCC tissues, suggesting the need for larger cohorts to strengthen the conclusions.
- Further Mechanistic Studies: While the study identifies the E2F1/miR-375/SESN3 axis and its link to the PI3K/AKT pathway, further research is needed to fully elucidate the intricate mechanisms involved.
- Therapeutic Strategies: The authors suggest exploring the involvement of the PI3K/AKT pathway in E2F1/miR-375/SESN3-mediated ESCC progression in conjunction with PI3K/AKT inhibitors. This points towards future therapeutic development based on targeting this axis.
Summary updated